Table 2 Estimation of cancer risk in IgG4-RD patients.
Cancer (ICD-10 code) | Total (n = 1627, 4085.20 PY) | Men (n = 729, 2285.02 PY) | Women (n = 538, 1800.17 PY) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Observed a | Expected b | SIR (95% CI) | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | |
All cancer | 147 | 35.7 | 4.12 (3.48–4.85) | 83 | 24.1 | 3.45 (2.75–4.28) | 64 | 11.6 | 5.51 (4.25–7.04) |
Solid cancer (C00–C80) | 110 | 33.0 | 3.33 (2.74–4.02) | 63 | 22.2 | 2.83 (2.18–3.62) | 47 | 10.8 | 4.36 (3.20–5.80) |
Hepatobiliary cancer | |||||||||
Liver (C22) | 10 | 2.4 | 4.18 (2.00-7.69) | 8 | 2.0 | 3.97 (1.71–7.82) | 2 | 0.4 | 5.31 (0.60-19.16) |
Pancreas (C25) | 16 | 1.1 | 14.54 (8.31–23.62) | 11 | 0.8 | 14.57 (7.26–26.08) | 5 | 0.3 | 14.48 (4.67–33.80) |
Gallbladder/biliary tract (C23–C24) | 12 | 1.0 | 11.85 (6.12–20.71) | 8 | 0.7 | 10.99 (4.73–21.66) | 4 | 0.3 | 14.05 (3.78–35.97) |
Reproductive cancer | |||||||||
Breast (C50) | 8 | 2.6 | 3.06 (1.32–6.02) | 0 | 8 | 2.6 | 3.08 (1.33–6.07) | ||
Ovary (C56) | 2 | 0.3 | 6.85 (0.77–24.74) | NA | 2 | 0.3 | 6.85 (0.77–24.74) | ||
Cervix uterus (C53) | 1 | 0.3 | 3.21 (0.04–17.87) | NA | 1 | 0.3 | 3.21 (0.04–17.87) | ||
Corpus uterus (C54) | 1 | 0.4 | 2.80 (0.04–15.58 | NA | 1 | 0.4 | 2.8 (0.04–15.58) | ||
Prostate (C61) | 11 | 3.4 | 3.22 (1.60–5.76) | 11 | 3.4 | 3.22 (1.60–5.76) | NA | ||
Respiratory cancer | |||||||||
Lung (C33–C34) | 7 | 4.8 | 1.46 (0.58-3.00) | 6 | 3.9 | 1.54 (0.56–3.36) | 1 | 0.9 | 1.09 (0.01–6.09) |
Lip, oral cavity, and pharynx (C00–C14) | 1 | 0.6 | 1.69 (0.02–9.40) | 0 | 1 | 0.1 | 9.42 (0.12–52.40) | ||
Gastrointestinal cancer | |||||||||
Stomach (C16) | 10 | 4.5 | 2.23 (1.07–4.10) | 5 | 3.6 | 1.40 (0.45–3.28) | 5 | 0.9 | 5.40 (1.74–12.59) |
Colon and rectum (C18–C20) | 13 | 4.1 | 3.15 (1.68–5.39) | 6 | 3.0 | 1.98 (0.72–4.32) | 7 | 1.1 | 6.37 (2.55–13.12) |
Urinary cancer | |||||||||
Kidney (C64) | 2 | 0.9 | 2.31 (0.26–8.35) | 1 | 0.7 | 1.48 (0.02–8.26) | 1 | 0.2 | 5.24 (0.07–29.14) |
Bladder (C67) | 6 | 0.8 | 7.38 (2.69–16.06) | 5 | 0.7 | 6.80 (2.19–15.86) | 1 | 0.1 | 12.90 (0.17–71.80) |
Skin cancer | |||||||||
Melanoma (C43) | 1 | 0.1 | 12.11 (0.16–67.35) | 1 | 0.1 | 18.32 (0.24-101.94) | 0 | ||
Non-melanoma of the skin (C44) | 1 | 0.8 | 1.30 (0.02–7.22) | 1 | 0.5 | 2.06 (0.03–11.44) | |||
Other | |||||||||
Thyroid (C73) | 4 | 3.0 | 1.33 (0.36–3.41) | 1 | 0.8 | 1.19 (0.02–6.60) | 3 | 2.2 | 1.39 (0.28–4.06) |
Central nervous system (C70–C72) | 3 | 0.2 | 13.32 (2.68–38.93) | 3 | 0.1 | 20.12 (4.04–58.77) | 0 | ||
Hematological cancer (C81–C86, C90–C96, D46, D47.1) | 28 | 1.8 | 15.31 (10.17–22.13) | 14 | 1.3 | 10.98 (6.00-18.43) | 14 | 0.6 | 25.28 (13.81–42.41) |
MDS (D46) | 10 | 0.2 | 49.46 (23.68–90.97) | 3 | 0.2 | 19.57 (3.93–57.19) | 7 | 0.0 | 143.16 (57.36-294.99) |
Non-Hodgkin lymphoma (C82–C86, C96) | 14 | 0.7 | 19.95 (10.90-33.47) | 10 | 0.5 | 20.25 (9.70-37.25) | 4 | 0.2 | 19.23 (5.17–49.23) |
Multiple myeloma (C90) | 3 | 0.3 | 11.13 (2.24–32.51) | 1 | 0.2 | 5.38 (0.07–29.91) | 2 | 0.1 | 23.93 (2.69–86.39) |
Leukemia (C91–C95) | 1 | 0.4 | 2.39 (0.03–13.31) | 0 | 1 | 0.1 | 7.40 (0.10-41.19) | ||
